Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Randomised, Placebo-controlled Trial Evaluating the Efficacy and Safety of Oral Nerandomilast Treatment in Patients With Systemic Sclerosis (SSc)

NCT07497087 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT07497087
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07497087 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Randomised, Placebo-controlled Trial Evaluating the Efficacy and Safety of Oral Nerandomilast Treatment in Patients With Systemic Sclerosis (SSc)
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Recruiting
Start date
July 27, 2026
Completion date
March 17, 2030
Enrollment
448 (estimated)
Sites
248

Conditions

As the registry lists them; a condition with its own page is linked.

systemic sclerosis